Skip to Content
Morningstar
Get 14 Days Free

Bausch Health Companies Inc BHC

Morningstar Rating
Rating as of

Morningstar’s Analysis

Valuation
Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

Capital Allocation

PREMIUM

Bausch Health Divestitures Accelerate Debt Paydown and Spin-Off Plans; Few Surprises in Q3 Earnings

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

While Bausch Health's third-quarter earnings did not provide much surprise, the company announced an acceleration of the Bausch and Lomb and Solta Medical spin-offs. We are maintaining our $26 fair value estimate (CAD 32) and no-moat rating, and there is no change to our long-term expectations. We intend to re-evaluate our valuation of Bausch Health once more details are disclosed on the upcoming spun businesses in early 2022.

Read Full Analysis

Company Profile

Business Description

Formerly known as Valeant Pharmaceuticals, Bausch Health is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in four segments: Bausch+Lomb and international (55% of revenue), Salix Pharmaceuticals (25%), ortho dermatology (6%), and diversified products (14%), and approximately 13% of revenue is attributable to non-U.S. markets. Bausch is the market leader in consumer visioncare in India and China and the fourth- largest visioncare company by sales in the United States.

Contact
2150 Saint Elzear Boulvard West
Laval, QC, H7L 4A8, Canada
T +1 514 744-6792
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type —
Employees 21,600

Related

Rekenthaler Report
From the Archives: 3 Lessons From Hedge Funds' Rise and (Partial) Fall
The ups and downs each inform.
John Rekenthaler
Investing Specialists
Stop the Mutual Fund Capital Gains Distribution Madness!
Some funds are likely to make big payouts again this year, but you don't have to take them lying down.
Christine Benz
ETF Specialist
Why Diversification Beats Conviction
The more concentrated a portfolio is, the greater the risk of missing out on the market's biggest winners and underperforming.
Alex Bryan
Stock Analyst Update
Valeant's Not Out of the Woods Yet
Although first-quarter results showed positive signs, debt remains a significant concern.
Michael Waterhouse
Fund Spy
Sorting the Rebels From the Conformists
Tracking error helps you set expectations.
Russel Kinnel
Stock Strategist
Concerns About Allergan's Health Are Overblown
The stock price implies the worst-case scenario for this wide-moat company.
Michael Waterhouse
Stock Analyst Update
Valeant: Business Shows Some Stability, But ...
We continue to have modest expectations for new products and the pipeline.
Michael Waterhouse
Our Picks
10 Solid Value Stocks at Great Prices (and 10 to Pass Up)
We examined the nearly 500 holdings in the Morningstar US Value Index and found some solid stocks at great prices, and others that look too expensive.
Karen Wallace
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended March 17.
Morningstar.com
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended March 10.
Morningstar.com
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended March 3.
Morningstar.com
Fund Times
Sequoia's Foundation Looks Stronger Than It Was Before
Despite continued poor performance, there's reason for optimism at this Bronze-rated fund.
Kevin McDevitt
Fund Spy
The Year in U.S. Equity Funds: Resilient in a Tumultuous 2016
In a year of unexpected events, U.S. stocks rose again with small caps outperforming for the first time since 2013.
Andrew Daniels
Investing Specialists
Morningstar's Most Popular for 2016
We look back at what you've read, watched, and researched over the past year.
Morningstar.com
Fund Spy
The 11 Biggest Manager Changes of 2016
This one goes to 11.
Russel Kinnel
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Dec. 9.
Morningstar.com
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Dec. 2.
Morningstar.com
Investing Specialists
Morningstar Runs the Numbers
We take a numerical look through this week's Morningstar research. Plus, our most popular articles and videos for the week ended Nov. 25.
Morningstar.com
Fund Times
We Boosted PIMCO High Yield's Rating to Silver
This deep and experienced team's deft navigation of recent energy-sector troubles has boosted our confidence here.
Sumit Desai, CFA
Market Update
Is It Time to Get Small?
Small-cap stocks took a beating last year, and despite the recent rebound, there are still good opportunities to be had.
Bryan Borzykowski